Almost all physicians write prescriptions, and each prescription requires a physician to assess the risks and benefits of the drug for their patient. If an adverse drug reaction occurs, physicians may be called on to defend their risk-benefit assessment in court. The assessment of risk is complicated when there is a black box warning that describes potentially serious and life-threatening adverse reactions associated with a drug. Some of our most commonly prescribed drugs have black box warnings, and drugs that were initially approved by the FDA without black box warnings may have them added years later.
Author: Praveen Suthrum
AbstractArtificial intelligence (AI), a discipline encompassed by data science, has seen recent rapid growth in its application to healthcare and beyond, and is now an integral part of daily life. Uses of AI in gastroenterology include the automated detection of disease and differentiation of pathology subtypes and disease severity. Although a majority of AI research in gastroenterology focuses on adult applications, there are a number of pediatric pathologies that could benefit from more research. As new and improved diagnostic tools become available and more information is retrieved from them, AI could provide physicians a method to distill enormous amounts of…
Gastroenterology is one of the most popular specialities in medicine. During gastroenterology speciality training, trainees can decide to further specialise in a sub-speciality. In 2015, a survey performed among gastroenterology residents in the Netherlands reported that the subspecialities most often chosen were ‘advanced’ endoscopy, hepatology, oncology and inflammatory bowel disease. The interest in neurogastroenterology was very limited. This contrasts with the prevalence of disorders of the gut brain-interaction (DGBIs), affecting 40% of the worldwide population.1 DGBIs are also the most frequent cause of consultation in patients presenting gastrointestinal symptoms in general practice.2 The lack of interest in irritable bowel syndrome…
Mental health symptoms in people who recovered from COVID-19 were associated with post-infection gastrointestinal (GI) symptoms, a survey-based study found. In an analysis of nearly 750 individuals who had COVID-19, those with mental health symptoms either before or after their infection were more than 16 times more likely to have post-COVID GI symptoms (adjusted odds ratio [aOR] 16.5, 95% CI 6.97-38.9), reported John Blackett, MD, MS, of the Mayo Clinic in Rochester, Minnesota, and colleagues.
Brian Dooreck, MD, of Pembroke Pines, Fla., explains why gastroenterologists can–and must–do a better job of communicating with their patients about a new diagnosis of colorectal cancer.
Biosimilars are making an impact in the GI field. Dr. Jennifer Caudle and Dr. Stephen Hanauer discuss the evolving role of biosimilars in anti-inflammatory care for GI patients.
Hello. I’m Dr David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia. I’ve just returned from the annual meeting of the American College of Gastroenterology (ACG), which was recently reported to be the largest gastroenterology association in the world. This year’s meeting was held in Las Vegas, live and in person, although there was a hybrid combination of virtual and onsite presence. It was so good to reconnect with colleagues and not have it be on a Zoom call.
New data released by the American Gastroenterological Association (AGA) shows 1 in 5 Americans are tolerating critical gastrointestinal (GI) symptoms and not seeking care. Even though GI conditions have become more mainstream in public conversations and media, these findings underscore a need for critical dialogue to engage patients in important decisions around their gastrointestinal health, and raise awareness around more concerning conditions like exocrine pancreatic insufficiency (EPI). The new data comes at a time when digestive diseases account for more than 100 million ambulatory care visits every year in the U.S. (NIH.gov). Yet, 1 in 4 (25%) report they would…
Dear colleagues and friends, I am fortunate to receive the baton from Charles Kahi, MD, in facilitating the fascinating and timely debates that have characterized the AGA Perspective series. Favorable reimbursement changes and the need for social distancing fast-tracked telemedicine, a care delivery model that had been slowly evolving.
Finding suitable biomarkers for patients with inflammatory bowel disease (IBD), either Crohn’s disease or ulcerative colitis, can be challenging. But by identifying and targeting biomarkers, clinicians can target earlier interventions and treatments that ultimately could result in better care. In data presented during the 2021 American College of Gastroenterology (ACG) Annual Meeting, a team led by Marla C. Dubinsky, MD, Professor of Pediatrics, Icahn School of Medicine at Mount Sinai, found patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein (CRP) and fecal calprotectin (fCLP) in a cohort of patients treated with…